HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats.
J Pharm Biomed Anal
; 150: 39-42, 2018 Feb 20.
Article
en En
| MEDLINE
| ID: mdl-29216583
ABSTRACT
Mesupron, the first-in-class inhibitor of urokinase-type plasminogen activator (uPA) is known to regulate cell proliferation and migration, and is under investigation for the treatment of metastatic breast cancer. In this study, a quantification method was developed for the determination of mesupron in rat plasma using liquid chromatography with a tandem mass spectrometry (LC-MS/MS). After protein precipitation with acetonitrile including itraconazole (internal standard, IS), the analytes were chromatographed on a reversed phased column with a mobile phase of acetonitrile and water (73, v/v, including 0.1% formic acid). The ion transitions of the precursor to the product ion were principally protonated ion [M+H]+ at m/z 630.4â398.3 for mesupron and 705.2â392.1 for the IS. The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods This method was successfully applied to a pharmacokinetic study of mesupron after intravenous administration in rats.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Sulfonamidas
/
Cromatografía Líquida de Alta Presión
/
Espectrometría de Masas en Tándem
/
Antineoplásicos
Límite:
Animals
Idioma:
En
Revista:
J Pharm Biomed Anal
Año:
2018
Tipo del documento:
Article
País de afiliación:
Corea del Sur